Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Ting‐Chao Chou, Paul Talalay · Advances in Enzyme Regulation · 1984 · 7.2K citations

Pharmacy, Pharmacokinetics, Pharmacology +16

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Paul G. Richardson, Bart Barlogie, James R. Berenson et al. · New England Journal of Medicine · 2003 · 2.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Safety and antitumor activity of recombinant soluble Apo2 ligand

Avi Ashkenazi, Roger Pai, Sharon Fong et al. · Journal of Clinical Investigation · 1999 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +17

The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB

Vito J. Palombella, Oliver J. Rando, Alfred L. Goldberg et al. · Cell · 1994 · 2.1K citations

Life Sciences, Biochemistry, Molecular Biology +11

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Teru Hideshima, Paul G. Richardson, D Chauhan et al. · PubMed · 2001 · 1.5K citations

Medicine, Oncology, Pharmacology +17